Levels of serum procalcitonin and C-reactive protein for evaluating pulmonary bacterial infection in patients with lupus erythematosus

Abstract

The severity of systemic lupus erythematosus (SLE) patients with pulmonary bacterial infection varies widely. We investigated the significance of procalcitonin (PCT) and C-reactive protein (CRP) in evaluating the severity of pulmonary infection in SLE patients. This retrospective study contained a total of 117 patients (107 women and 10 men) with SLE from January 2010 to June 2011. Serum levels of PCT and CRP were measured by enzyme-linked immunosorbent assay. The severity of pulmonary bacterial infection (PBI) was evaluated using the pneumonia severity index (PSI). SLE patients with PBI, particularly those with bacterial isolates, had significantly higher levels of serum PCT and CRP than those without PBI. Serum PCT and CRP were not associated with SLE disease activity, but positively with the values of PSI in active SLE patients with PBI. Serum levels of PCT and CRP may be additional biomarkers in evaluating the severity of PBI in lupus patients.

Keywords

systemic lupus erythematosus / procalcitonin / C-reactive protein / pulmonary infection

References

[1] Pons-EstelGJ, AlarconGS, ScofieldL, et al. . Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum, 2010, 39(4): 257-268 PMID: 19136143

[2] SmithPP, GordonC. Systemic lupus erythematosus: clinical presentations. Autoimmun Rev, 2010, 10(1): 43-45 PMID: 20850569

[3] SciasciaS, CuadradoMJ, KarimMY. Management of infection in systemic lupus erythematosus. Best Pract Res Clin Rheumatol, 2013, 27(3): 377-389 PMID: 24238694

[4] MokCC, LeeKW, HoCT, et al. . A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford), 2000, 39(4): 399-406

[5] Navarro-ZarzaJE, Alvarez-HernandezE, Casasola-VargasJC, et al. . Prevalence of community-acquired and nosocomial infections in hospitalized patients with systemic lupus erythematosus. Lupus, 2010, 19(1): 43-48 PMID: 19884213

[6] SegalBH, SnellerMC. Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am, 1997, 23(2): 219-237 PMID: 9156390

[7] NavarraSV, LeynesMS. Infections in systemic lupus erythematosus. Lupus, 2010, 19(12): 1419-1424 PMID: 20947551

[8] MullerB, HarbarthS, StolzD, et al. . Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis, 2007, 7: 10 PMID: 17335562 PMCID: 1821031

[9] SimonL, GauvinF, AmreDK, et al. . Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis, 2004, 39(2): 206-217 PMID: 15307030

[10] LanoixJP, BourgeoisAM, SchmidtJ, et al. . Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus, 2011, 20(2): 125-130 PMID: 20937623

[11] KimMH, LimG, KangSY, et al. . Utility of procalcitonin as an early diagnostic marker of bacteremia in patients with acute fever. Yonsei Med J, 2011, 52(2): 276-281 PMID: 21319346 PMCID: 3051230

[12] Bellmann-WeilerR, AusserwinklerM, KurzK, et al. . Clinical potential of C-reactive protein and procalcitonin serum concentrations to guide differential diagnosis and clinical management of pneumococcal and Legionella pneumonia. J Clin Microbiol, 2010, 48(5): 1915-1917 PMID: 20220163 PMCID: 2863928

[13] Giamarellos-BourboulisEJ, TsangarisI, KanniT, et al. . Procalcitonin as an early indicator of outcome in sepsis: a prospective observational study. J Hosp Infect, 2011, 77(1): 58-63 PMID: 21131099

[14] KotoulaA, GardikisS, TsalkidisA, et al. . Procalcitonin for the early prediction of renal parenchymal involvement in children with UTI: preliminary results. Int Urol Nephrol, 2009, 41(2): 393-399 PMID: 18836845

[15] HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1997, 40(9): 1725 PMID: 9324032

[16] BombardierC, GladmanDD, UrowitzMB, et al. . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35(6): 630-640

[17] FineMJ, AubleTE, YealyDM, et al. . A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med, 1997, 336(4): 243-250 PMID: 8995086

[18] GuerinS. Evaluation of the detection of procalcitonin by an immuno-chromatography test: Brahms PCT-Q. Ann Biol Clin (Paris), 2000, 58(5): 613-614

[19] EberhardOK, HaubitzM, BrunkhorstFM, et al. . Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/ systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum, 1997, 40(7): 1250-1256 PMID: 9214425

[20] QuintanaG, MedinaYF, RojasC, et al. . The use of procalcitonin determinations in evaluation of systemic lupus erythematosus. J Clin Rheumatol, 2008, 14(3): 138-142 PMID: 18525431

[21] KimHA, JeonJY, AnJM, et al. . C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. J Rheumatol, 2012, 39(4): 728-734 PMID: 22337236

[22] BadorKM, IntanS, HussinS, et al. . Serum procalcitonin has negative predictive value for bacterial infection in active systemic lupus erythematosus. Lupus, 2012, 21(11): 1172-1177 PMID: 22652631

[23] UramotoKM, MichetCJ, ThumbooJ, et al. . Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum, 1999, 42(1): 46-50 PMID: 9920013

[24] RowtherFB, RodriguesCS, DeshmukhMS, et al. . Prospective comparison of Eubacterial PCR and measurement of procalcitonin levels with blood culture for diagnosing septicemia in intensive care unit patients. J Clin Microbiol, 2009, 47(9): 2964-2969 PMID: 19641068 PMCID: 2738124